Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 33 of 33 matching drugs for ADRB3 — including drugs targeting any of its 13 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
carboplatin, 3 dimensional conformal radiation therapy, propranolol, intensity modulated radiation therapy, paclitaxel ADRB3 Direct 1
durvalumab, gemcitabine, nab paclitaxel, tremelimumab, propranolol, cisplatin ADRB3 Direct 1
propranolol, esophageal variceal ligation ADRB3 Direct 1
propranolol, placebo ADRB3 Direct 1
carteolol ADRB3 Direct yes 0
carteolol hydrochloride ADRB3 Direct yes 0
carvedilol ADRB3 Direct yes 0
carvedilol phosphate ADRB3 Direct yes 0
dilevalol ADRB3 Direct yes 0
dilevalol hydrochloride ADRB3 Direct yes 0
dipivefrin ADRB3 Direct yes 0
dipivefrin hydrochloride ADRB3 Direct yes 0
ephedrine ADRB3 Direct yes 0
ephedrine hydrochloride ADRB3 Direct yes 0
ephedrine sulfate ADRB3 Direct yes 0
epinephrine ADRB3 Direct yes 0
epinephrine bitartrate ADRB3 Direct yes 0
hydroxyamphetamine ADRB3 Direct yes 0
hydroxyamphetamine hydrobromide ADRB3 Direct yes 0
isoproterenol ADRB3 Direct yes 0
isoproterenol hydrochloride ADRB3 Direct yes 0
isoproterenol sulfate ADRB3 Direct yes 0
labetalol ADRB3 Direct yes 0
labetalol hydrochloride ADRB3 Direct yes 0
mephentermine ADRB3 Direct yes 0
mephentermine sulfate ADRB3 Direct yes 0
mirabegron ADRB3 Direct yes 0
norepinephrine ADRB3 Direct yes 0
norepinephrine bitartrate ADRB3 Direct yes 0
vibegron ADRB3 Direct yes 0
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy NFKB2 SSL via NFKB2 1
sulfasalazine NFKB2 SSL via NFKB2 1
ataluren RPL22 SSL via RPL22 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.